Q: Droxidopa after decarboxylation worked as a which pressor or inotrope? - Select one
A) Dopamine
B) Dobutamine
C) Epinephrine
D) Norepinephrine
E) Vasopressin
Answer: D
Droxidopa has recently become widely used in ICUs to treat vasoplegia or persistent hypotension. Droxidopa is L-dihydroxyphenylserine, also known as (DOPS). It is an oral synthetic amino acid, identical to levodopa but with an added hydroxyl group. After oral administration, droxidopa is decarboxylated to norepinephrine, the naturally occurring sympathetic neurotransmitter. Patients with neurogenic orthostatic hypotension (nOH) retain the ability to convert droxidopa to norepinephrine, which helps in overcoming hypotension.
The starting dose is 100 mg three times daily, up to a total of 1800 mg in three divided doses.
One caveat are the patients with Parkinson disease who are on high doses of carbidopa (more than 200 mg/day) as carbidopa blocks the conversion of droxidopa to norepinephrine.
Side effects are supine hypertension, headache, and nausea.
#hrmodynamics
#pharmacology
#neurology
References:
1. Biaggioni I, Arthur Hewitt L, Rowse GJ, Kaufmann H. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol 2017; 17:90.
2. Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis 2014; 4:57.
3. Kaufmann H, Norcliffe-Kaufmann L, Palma JA. Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther 2015; 13:875.
